- Home
- LNKB vs MREO Comparison
LNKB vs MREO Comparison
Compare LNKB & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- MREO
- Stock Information
- Founded
- LNKB 2018
- MREO 2015
- Country
- LNKB United States
- MREO United Kingdom
- Employees
- LNKB N/A
- MREO N/A
- Industry
- LNKB
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- MREO Health Care
- Exchange
- LNKB Nasdaq
- MREO Nasdaq
- Market Cap
- LNKB 261.4M
- MREO 311.8M
- IPO Year
- LNKB N/A
- MREO N/A
- Fundamental
- Price
- LNKB $6.96
- MREO $1.93
- Analyst Decision
- LNKB Strong Buy
- MREO Strong Buy
- Analyst Count
- LNKB 1
- MREO 5
- Target Price
- LNKB $9.00
- MREO $7.40
- AVG Volume (30 Days)
- LNKB 110.7K
- MREO 1.5M
- Earning Date
- LNKB 10-27-2025
- MREO 11-12-2025
- Dividend Yield
- LNKB 4.29%
- MREO N/A
- EPS Growth
- LNKB 512.12
- MREO N/A
- EPS
- LNKB 1.03
- MREO N/A
- Revenue
- LNKB $122,594,000.00
- MREO $500,000.00
- Revenue This Year
- LNKB $18.26
- MREO N/A
- Revenue Next Year
- LNKB N/A
- MREO $72.16
- P/E Ratio
- LNKB $6.78
- MREO N/A
- Revenue Growth
- LNKB 42.32
- MREO N/A
- 52 Week Low
- LNKB $6.09
- MREO $1.47
- 52 Week High
- LNKB $7.98
- MREO $4.40
- Technical
- Relative Strength Index (RSI)
- LNKB 43.70
- MREO 45.27
- Support Level
- LNKB $6.85
- MREO $1.89
- Resistance Level
- LNKB $7.10
- MREO $2.15
- Average True Range (ATR)
- LNKB 0.19
- MREO 0.12
- MACD
- LNKB -0.01
- MREO -0.03
- Stochastic Oscillator
- LNKB 11.32
- MREO 2.57
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).